Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Early-stage Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Atezolizumab|DRUG: Trastuzumab emtansine|DRUG: Paclitaxel
Sponsor: Renske Altena